Compare Novo Nordisk A/S (NVO) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Zillow Group Inc Class C — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Zillow Group Inc Class C trades at $32 (market cap $7.54B). The key difference: Novo Nordisk A/S is far larger — about 29.2× Zillow Group Inc Class C's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| NVO | Z | |
|---|---|---|
Market Cap | $220.53B | $7.54B |
Sector | Health | Media |
52-Week High | $71.70 | $90.35 |
52-Week Low | $35.29 | $29.41 |
Enterprise Value | $239.49B | $7.19B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Zillow Group (Z) trades at $33.03, down 2.58% amid legal headwinds, with technicals neutral and fundamentals showing improving profitability. Revenue grew to $2.58B in 2025 with net income turning positive at $23M, though valuation multiples remain elevated with a P/E of 132.04. The stock faces significant legal overhang from multiple class-action lawsuits alleging securities fraud related to an anticompetitive agreement.
The outlook is cautious; while earnings beat expectations in two recent quarters and analyst consensus targets $57.67, near-term risks from litigation and a high P/E ratio temper upside potential. Investment appeal hinges on legal resolution and sustained margin expansion beyond current modest levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
